Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30959359 | 0.82 | DGAT2 (0.33) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL30959508 | 0.82 | CYP4F2 (0.35) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL31527384 | 0.82 | DGAT2 (0.35) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL30858862 | 0.82 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL20581028 | 0.82 | RXRA (0.37) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL20938994 | 0.81 | RXRA (0.41) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL30602777 | 0.81 | RXRA (0.41) | RXRARXRBRXRGDGAT2CYP4F2 | |
| SCHEMBL20939437 | 0.78 | KRAS (0.38) | RXRARXRBRXRGLMNAPOLB | |
| SCHEMBL22584363 | 0.78 | KRAS (0.38) | RXRARXRBRXRGLMNAPOLB | |
| SCHEMBL22584365 | 0.78 | KRAS (0.38) | RXRARXRBRXRGLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2023-01-10 | — | — | US | disclosed |
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-10-29 | — | — | US | disclosed |
| EP-3697791-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS Innopharm (Shanghai) Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019076358-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019076358-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | IDO1, TDO2, IDO2 | RXRA 3487/4885RXRB 3197/4885RXRG 2940/4885 |
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | IDO1, TDO2, IDO2 | RXRA 3487/4885RXRB 3197/4885RXRG 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.